126
Views
30
CrossRef citations to date
0
Altmetric
Original Research

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A

, , &
Pages 55-61 | Published online: 14 Mar 2011

References

  • LjungRProphylactic therapy in hemophiliaBlood Rev20092326727419775786
  • PipeSAntihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia ABiologics2009311712519707401
  • MinersARevisiting the cost-effectiveness of primary prophylaxis with clotting factor for the treatment of severe haemophilia AHaemophilia200915488188719473422
  • GringeriAMantovaniLGScaloneLMannucciPMFor the COCIS Study GroupCost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group2003102723582363
  • Donadel-ClaeyssensSEuropean Paediatric Network for Haemophilia Management; Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management)Haemophilia200612212412716476085
  • Manco-JohnsonMJAbshireTCShapiroADProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophiliaN Engl J Med2007357653554417687129
  • MinersAHSabinCATolleyKHLeeCACost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophiliaPharmacoeconomics2002201175977412201795
  • DrummondMFSchulpherMJTorranceGWO’BrienBJStoddartGLMethods for the Economic Evaluation of Health Care Programmes3rd edOxfordOxford University Press2005
  • SonnenbergFABeckJRMarkov models in medical decision making: a practical guideMed Decis Making19931343223388246705
  • BriggsASculpherMAn introduction to Markov modelling for economic evaluationPharmacoeconomics199813439740910178664
  • Demo.istat.it [homepage on the internet]. Italian National Institute of StatisticsAge specific death rates by gender [updated 2007] http://demo.istat.it/unitav/index.html?lingua=ita. Accessed January 11, 2010.
  • Salute.gov.it. [homepage on the internet]. Italian Ministry of Health http://www.salute.gov.it/ricoveriOspedalieri/ric_informazioni/default.jsp. Accessed February 12, 2010.
  • MinersAHSabinCATolleyKHJenkinsonCKindPLeeCAAssessing health-related quality-of-life in individuals with haemophiliaHaemophilia19995637838510583523
  • LaupacisABourneRRorabeckCThe effect of elective total hip replacement on health-related quality of lifeJ Bone Joint Surg Am19937511161916268245054
  • SantagostinoEMannucciPMBianchi BonomiAGuidelines on replacement therapy for haemophilia and inherited coagulation disorders in ItalyHaemophilia20006111010632734
  • TagliaferriAFranchiniMCoppolaAEffects of secondary prophylaxis started in adolescent and adult haemophiliacsHaemophilia200814594595118540895
  • Informatore FarmaceuticoElsevier2010
  • GeraghtySDunkleyTHarringtonCLindvallKMaahsJSekJPractice patterns in haemophilia A therapy – global progress towards optimal careHaemophilia2006121758116409179
  • LucioniCRavasioRCome valutare i risultati di uno studio farmacoeconomico?PharmacoEconomics – Italian Research Articles20043121130
  • MessoriASantarlasciBTrippoliSVaianiMControvalore economico del farmaco e beneficio clinico: Stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomicoPharmacoEconomics – Italian Research Articles200355367
  • Associazione Italiana di Economia Sanitaria (AIES)Proposta di linee guida per la valutazione economica degli interventi sanitariPharmacoEconomics – Italian Research Articles2009118393
  • GringeriAProspective controlled studies on prophylaxis: an Italian approachHaemophilia20039Suppl 1S38S42